opc 28326 has been researched along with alprostadil in 1 studies
Studies (opc 28326) | Trials (opc 28326) | Recent Studies (post-2010) (opc 28326) | Studies (alprostadil) | Trials (alprostadil) | Recent Studies (post-2010) (alprostadil) |
---|---|---|---|---|---|
9 | 1 | 1 | 7,136 | 864 | 761 |
Protein | Taxonomy | opc 28326 (IC50) | alprostadil (IC50) |
---|---|---|---|
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 2.3 | |
Solute carrier organic anion transporter family member 2B1 | Rattus norvegicus (Norway rat) | 0.0358 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, R; Kambayashi, JI; Li, J; Lockyer, S; Sun, B; Yoshitake, M | 1 |
1 other study(ies) available for opc 28326 and alprostadil
Article | Year |
---|---|
OPC-28326, a selective femoral vasodilator, is an alpha2C-adrenoceptor-selective antagonist.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Alprostadil; Aniline Compounds; Animals; CHO Cells; Cloning, Molecular; Cricetinae; Femoral Vein; Hindlimb; In Situ Hybridization; In Vitro Techniques; Luciferases; Male; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Vasodilator Agents; Yohimbine | 2001 |